AR123760A1 - METHODS TO TREAT CANCER - Google Patents
METHODS TO TREAT CANCERInfo
- Publication number
- AR123760A1 AR123760A1 ARP210102808A ARP210102808A AR123760A1 AR 123760 A1 AR123760 A1 AR 123760A1 AR P210102808 A ARP210102808 A AR P210102808A AR P210102808 A ARP210102808 A AR P210102808A AR 123760 A1 AR123760 A1 AR 123760A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- her2
- egfr
- disorder
- disease
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000005829 chemical entities Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 239000000890 drug combination Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación proporciona entidades químicas (p. ej., un compuesto o una sal farmacéuticamente aceptable, y/o un hidrato, y/o un cocristal, y/o una combinación de fármacos del compuesto) que inhiben el receptor del factor de crecimiento epidérmico (EGFR, ERBB1) y/o el receptor del factor de crecimiento epidérmico humano 2 (HER2, ERBB2). Estas entidades químicas son útiles, p. ej., para tratar una afección, enfermedad o trastorno en que el aumento (p. ej., excesivo) de la activación del EGFR y/o del HER2 contribuye a la patología y/o a los síntomas y/o a la progresión de la afección, enfermedad o trastorno (p. ej., cáncer) en un sujeto (p. ej., un humano). La presente divulgación también proporciona composiciones que las contienen, así como métodos de uso y fabricación de estas.The present disclosure provides chemical entities (eg, a compound or a pharmaceutically acceptable salt, and/or a hydrate, and/or a co-crystal, and/or a drug combination of the compound) that inhibit growth factor receptor epidermal (EGFR, ERBB1) and/or human epidermal growth factor receptor 2 (HER2, ERBB2). These chemical entities are useful, e.g. to treat a condition, disease, or disorder in which increased (eg, excessive) activation of EGFR and/or HER2 contributes to the pathology and/or symptoms and/or progression of the condition , disease or disorder (eg, cancer) in a subject (eg, a human). The present disclosure also provides compositions containing them, as well as methods of using and manufacturing them.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089965P | 2020-10-09 | 2020-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123760A1 true AR123760A1 (en) | 2023-01-11 |
Family
ID=85131307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102808A AR123760A1 (en) | 2020-10-09 | 2021-10-12 | METHODS TO TREAT CANCER |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR123760A1 (en) |
-
2021
- 2021-10-12 AR ARP210102808A patent/AR123760A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000856A1 (en) | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer | |
| PY2089151A (en) | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING'S ACTIVITY | |
| PY2026348A (en) | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING'S ACTIVITY | |
| CY1123305T1 (en) | SUBSTITUTED IMIDAZO-QUINOLINES AS NLRP3 REGULATORS | |
| PY2089159A (en) | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING'S ACTIVITY | |
| BR112023006531A2 (en) | HETEROCYLIC EGFR AND/OR HER2 INHIBITORS, FOR USE IN THE TREATMENT OF CANCER | |
| CL2023003691A1 (en) | Urea derivatives that can be used to treat cancer | |
| PY2060666A (en) | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING'S ACTIVITY | |
| PY2157405A (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH STING ACTIVITY | |
| CL2020002748A1 (en) | Cyclin-dependent kinase inhibitors | |
| PE20191303A1 (en) | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS THAT HAVE MUTATIONS IN EXON 20 OF EGFR OR HER2 | |
| DOP2019000020A (en) | TIAZOLO-PYRIDINE COMPOUNDS REPLACED AS INHIBITORS OF MALT1 | |
| UY39608A (en) | COMPOUNDS AND COMPOSITIONS TO TREAT CONDITIONS ASSOCIATED WITH STING ACTIVITY | |
| UY35369A (en) | Quinazolinic inhibitors of mutated epidermal growth factor receptor activating forms | |
| CL2024000327A1 (en) | Compounds that inhibit the alpha isoform of pi3k and methods for treating cancer | |
| UY40106A (en) | Compounds and compositions for treating conditions related to STING activity | |
| WO2022072645A3 (en) | Pyrrolopyrolidinone and pyrroloazepinone derivatives for use in treating cancer | |
| CL2024000385A1 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| CO2024009091A2 (en) | Heterocyclic compounds as inhibitors of dyrk1a | |
| AR123760A1 (en) | METHODS TO TREAT CANCER | |
| AR123576A1 (en) | METHODS TO TREAT CANCER | |
| MX2020010121A (en) | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS CARRYING MUTATIONS IN EXON 19 OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2. | |
| AR132891A1 (en) | METHODS FOR TREATING CANCER | |
| AR132892A1 (en) | METHODS FOR TREATING CANCER | |
| CO2019001967A2 (en) | Thiazolo-pyridine substituted compounds as malt1 inhibitors |